Clinical Trial to Investigate the Pharmacokinetics and Safety of CKD-393

T2DM (Type 2 Diabetes Mellitus) Clinical Trial

Official title:

A Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety of CKD-393 and Co-administration of CKD-501, D759 and D150 Under Fed Condition in Healthy Adults

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04706286
• Other study ID #: A98_03BE2018
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: February 18, 2021
• Est. completion date: April 5, 2021

Study information

• Verified date: January 2021
• Source: Chong Kun Dang Pharmaceutical
• Contact: Choon Ok Kim, M.D., Ph.D.
• Phone: +82-2-2228-0455
• Email: DELIVERY98[@]yuhs.ac
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Clinical Trial to evaluate the Pharmacokinetics and safety of CKD-393 0.5/100/1000 mg under fed condition

Description:

A Phase 1 Clinical Trial to evaluate the safety and pharmacokinetics in healthy adult volunteers after administration of CKD-393 0.5/100/1000 mg under fed condition.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 26
• Est. completion date: April 5, 2021
• Est. primary completion date: March 29, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 19 Years to 55 Years

Eligibility

Inclusion Criteria:

1. Healthy adult who is 19 ~ 55 years at the time of screening

2. Body weight more than 55 kg for male and more than 50kg for female

3. BMI more than 18.5 kg/m2 or less than 27.0 kg/m2

4. Females must be menopause or surgical infertility

5. Males who have consented to the use of appropriate pregnancy contraceptive methods up to 28 days after the last investigational product and not to provide sperm

6. Subjects who voluntarily decided to participate and informed consent based upon understanding on the study.

Exclusion Criteria:

1. Subjects who have a history of clinically significant hepatic, renal, nervous, immune, respiratory, urinary, digestion, endocrine, hematooncology, cardiovascular systemic disease or psychosis disorder

2. Subjects who have genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption

3. Subjects with poor oral intake, susceptible to dehydration or clinically significant dehydration

4. Subjects who have a history of gastrointestinal disorders (Crohn's disease, ulcerative colitis, etc.) or surgery (except simple appendectomy or hernia surgery) that may affect the absorption of the drug

5. Subjects who have a history of clinically significant hypersensitivity to drugs or additives

6. Subjects who have severe infectious disease and severe trauma before and after operation

7. Subjects who have undergone i.v. testing of radioactive iodine contrast material within 48 hours before the first IP administration

8. Subjects who are deemed unsuitable as subjects in the screening test performed within 28 days before the administration of investigational product

• AST, ALT> UNL(Upper Normal Limit)x1.25

• eGFR (Estimated Glomerular Filtration Rate) <60 mL/min/1.73m2 using the MDRD (Modification of Diet in Renal Disease) equation

• Positive immunologic serological tests (hepatitis B test, hepatitis C test, human immunodeficiency virus (HIV) test, syphilis test)

• After resting for more than 5 minutes, systolic blood pressure> 150 mmHg or < 90 mmHg, diastolic blood pressure> 100 mmHg or <50 mmHg

9. Subjects who have had a history of drug abuse within one year of screening or have tested positive on urine drug screening test

10. Subjects who judged to able to affect in the study or in the subject's safety by the investigator for the following reasons

• Ethical-the-counter (ETC) drugs and herbal medicines within 14 days of the first administration of the investigational drug.

• Over-the-counter (OTC) drugs, including health foods and vitamin preparations, within 7 days of the first dose of the investigational product

• Inducing or inhibiting drugs of drug-metabolism enzyme, within 30 days of the first dose of the investigational product

11. Subjects who have consistently excessively smoked or consumed caffeine or alcohol (caffeine:> 5 cups / day, alcohol:> 210 g / week, cigarettes:> 10 cigarettes / day) or cannot stop smoking, consuming caffeine and alcohol during hospitalization

12. Subjects who take grapefruit-containing food within 7 days before IP administration, or cannot forbid taking grapefruit-containing food for period of clinical trials.

13. Subjects who have received the investigational product by participating in other clinical trials (including bioequivalence studies) within 180 days before the first dose of the investigational product (For biological agents, this may be based on a longer period of time, considering the half-life)

14. Subjects who donated whole blood within 60 days before the first dose of the investigational product or donated component blood donation within 30 days

15. Subjects who received a blood transfusion within 30 days before the first dose of the investigational product

16. Pregnant or lactating women

17. Subjects who were deemed to be inappropriate to participate in the study by the investigator judgment

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 2
• T2DM (Type 2 Diabetes Mellitus)

Intervention

Drug:
• CKD-501, D759, D150
CKD-501 0.5 mg 1T, D759 100 mg 1T and D150 1000 mg 1T, single oral administration under fed condition
• CKD-393 0.5/100/1000 mg
CKD-393 0.5/100/1000 mg 1T, single oral administration under fed condition

Locations

Country	Name	City	State
Korea, Republic of	Severance Hospital	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Chong Kun Dang Pharmaceutical

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	AUCt(Area Under Curve last) of CKD-393	Area under the plasma concentration time curve of CKD-393, from time zero up to the last measurable concentration.	From predose, upto 48 hours post-dose
Primary	Cmax of CKD-393	The maximum concentration observed of CKD-393 over blood sampling time.	From predose, upto 48 hours post-dose